• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Integral Diagnostics (ASX:IDX) Shares Reflect Cash Backed Recovery And Capex Risk

    Simply Wall St·08/26/2026 09:45:01
    语音播报

    Integral Diagnostics shareholders came into today with the stock grinding higher, up about 10% over three months and closing at A$2.33 on Wednesday. The market has been treating it like a slow repair story. The FY26 numbers tell a sharper tale. Operating net profit after tax reached A$47.4m and operating earnings per share hit A$0.126, while operating free cash flow of A$106.4m backed those profits with cash. The real question for you now is whether today’s calm price reaction reflects discipline or indifference to that cash backed recovery story.

    Is Integral Diagnostics really trading like a slow repair story, or is the market missing what that cash backed turnaround implies for fair value? Compare today’s A$2.33 share price with our valuation analysis for Integral Diagnostics

    FY 2026 Earnings Summary

    • Revenue, FY 2026 vs FY 2025: A$788.6m vs A$627.2m (increase of close to 26%)
    • Net Income, FY 2026 vs FY 2025: A$21.9m vs A$2.7m (increase of around 7x)
    • Basic EPS, FY 2026 vs FY 2025: A$0.0588 per share vs A$0.0088 per share (increase of around 7x)
    • Operating EBITDA Margin, FY 2026 vs FY 2025: 20.9% vs 20.1% (up 0.8 percentage points)

    Prefer clear visuals instead of another wall of EPS figures and cash flow tables? See Integral Diagnostics' valuation story pulled together in one clean, interactive view in our company report for Integral Diagnostics.

    ASX:IDX Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    ASX:IDX Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Integral Diagnostics’ Bull Case Meets Hard Operating Targets

    The positive narrative around Integral Diagnostics is that higher value imaging, teleradiology scale and AI supported workflows can lift margins and cash generation without overbuilding the network. FY26 goes a fair way to proving that out. Revenue grew faster than exam volumes as MRI, CT and PET/CT mix lifted average fees by 6.5%. Operating EBITDA margin moved to 20.9%, helped by more than A$14m of merger synergies and better procurement rather than one off cost cuts.

    The teleradiology arm IDXt is a key proof point. Radiologist headcount rose to 143 and now carries about 15% of group volumes, which supports the idea of easing regional bottlenecks and spreading fixed radiologist costs. Operating free cash flow of A$106.4m, at 82% conversion, backs the claim that this is becoming a more cash generative platform, not just a bigger one.

    Compare how that higher margin mix, teleradiology scale and strong cash conversion stack up against institutional expectations. See whether analysts think Integral Diagnostics is on track or off pace with the consensus price target analysis for Integral Diagnostics.

    Bear Case on Integral Diagnostics Tests Capital and Mix

    The bearish view on Integral Diagnostics is that growth relies too heavily on capital hungry MRI rollouts and lower fee screening work, which could trap margins and free cash flow. FY26 only partly disarms that. MRI licences jumped from 23 to 42 units and growth capex reached A$21.0m within A$49.8m of total capex. That confirms the capital intensity concern, even though operating free cash flow of A$106.4m and 82% conversion eased near term worries.

    Bears also argue that mix and labour pressure will cap margin progress. Operating EBITDA margin at 20.9% and organic revenue growth of about 7% show progress, but much of the uplift came from more than A$14m of integration synergies and Medicare indexation. Radiologist shortages and Capitol’s slower specialist referral build hurt the idea of an easy margin runway. The result challenges the harshest pessimism but does not fully clear the execution risk overhang.

    After interest cover pressure, one off items and dividend strain, review whether Integral Diagnostics faces deeper structural issues in our risk analysis for Integral Diagnostics which shows 3 important warning signs.

    Stay Ahead Of Your Next Move

    If Integral Diagnostics' cash backed turnaround and capex commitments have your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch how new results shift the picture. Once you decide to take a position, keep the noise down and your decisions focused by managing your holdings through the Portfolio Command Center that flags only the most important developments. For a longer term edge, compare your thinking on Integral Diagnostics with thousands of other investors through the Community and see which risks and catalysts others are watching. By surfacing potential turning points and red flags early, you give yourself a better chance of staying ahead of the market rather than reacting to it.

    Seeking Alternatives Beyond Integral Diagnostics?

    Fresh ideas often move first when momentum builds and prices start flying. Scan curated stock lists before the crowd, while it matters and the data is still under the radar for now. Act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.